News

Press Releases

Inflection Biosciences Announces Participation at Upcoming Industry Conferences.

Dublin, Ireland, May 12th, 2020 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...

Inflection Biosciences Announces Appointment of Shaun McNulty, Ph.D., as Chief Scientific Officer.

Dublin, Ireland, February 19th, 2020 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of...

Inflection Biosciences Announces Appointment of Murray Yule, M.D., Ph.D., as Chief Medical Officer

(06 Feb 2020) Dublin, Ireland, February 6th, 2020 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the...

Inflection Biosciences to present at BIO CEO & Investor Conference 2020.

Dublin, Ireland, January 31, 2020 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...

Inflection Biosciences Selected as Tech Tour Contest Finalist for 2019

Dublin, Ireland, November 26, 2019 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of...

Inflection Biosciences Announces Passing of Co-Founder and Board Member John Scanlan

Dublin, Ireland, October 30, 2019 – Inflection Biosciences Ltd today announced that John Scanlan, a co-founder and a member of its Board...

Inflection Biosciences Announces Pre-clinical Data to be Presented at IASLC 2019 World Conference.

Dublin, Ireland, September 9th, 2019 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of...

Inflection Biosciences Announces Publication of Positive Data for PIM/PI3K/mTOR Inhibitor

Dublin, Ireland, August 7, 2019 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...

Inflection Biosciences and AUM Biosciences announce Global License Agreement for PIM/PI3K/mTOR

Dublin, Ireland, 18 July 2019 – Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of...

Inflection Biosciences Announces Pre-clinical Data to be Presented at 2018 AACR Targeting PI3K/mTOR

Dublin, Ireland, November 28th, 2018 – Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today...